Nutcracker Therapeutics Raises $60 Million in Series B Round of Financing

By StartUp City | Monday, September 28, 2020

The ACORN platform is a computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips

FREMONT, CA: Nutcracker Therapeutics, a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, raised $60 million in Series B Round of financing led by ARCH Venture Partners with participation from other top healthcare investors including Bluebird Ventures, a firm associated with Sutter Hill Ventures.

Nutcracker has combined the productivity of RNA biology with innovations inspired by semiconductor manufacturing techniques to develop a proprietary miniaturized platform that allows the rapid discovery, development, and manufacturing of mRNA therapies and vaccines. The "GMP-in-a-box" ACORN platform is a first-of-its-kind, computer-controlled RNA manufacturing system that starts with a nucleic acid sequence of interest and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated, single-use biochips. All steps are performed in an automated, fully isolated microfluidic path, enabling rapid scalability and efficient manufacturing of high-quality products within smaller footprint facilities with reduced operating costs compared to conventional bioreactor manufacturing.

"RNA-based therapeutics are emerging as an important new class of medicines," said Dr.Khandros. "We founded Nutcracker based on our conviction that to fulfill the promise of RNA therapeutics, we must meld the productivity of RNA biology with semiconductor-like development and manufacturing controls and discipline. Our platform can efficiently create both patient-specific and broadly applicable RNA medicines and enables the rapid scaling of GMP manufacturing. We are applying the platform to develop Nutcracker's own RNA medicines, with an initial focus on mRNA therapies for oncology, and these programs will incorporate our proprietary delivery vehicles and mRNA designs. We are also establishing partnerships with other biopharma companies across a range of indications and RNA therapeutics."

Igor Khandros, Ph.D., is co-founder and chief executive officer of Nutcracker Therapeutics. Khandros previously founded three publicly traded companies, including FormFactor, and Berkeley Lights.

Weekly Brief